Uncategorized
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
Pathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of the AstraZeneca agreement were not disclosed. Read More